The Regulatory Pathway for Antifungal Drugs: A US Perspective

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S678-S683

  Tillotson, Joni ^a   Tillotson, Glenn S ^a  

^a TRANSCRIP PARTNERS LLP   (United Kingdom)

Author keywords

antifungal resistance; FDA; GAIN; orphan drug status; QIDP

Indexed keywords

ANTIFUNGAL AGENT; ORPHAN DRUG;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; CANDIDA; CLINICAL PRACTICE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; FUNGAL STRAIN; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; MUCORMYCOSIS; MYCOSIS; PATENT; PRIORITY JOURNAL; UNITED STATES; DRUG MANUFACTURE; LEGISLATION AND JURISPRUDENCE; MICROBIOLOGY; MYCOSES; ORGANIZATION AND MANAGEMENT;

ANTIFUNGAL AGENTS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; MYCOSES; ORPHAN DRUG PRODUCTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84950238867     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ819     Document Type: Article

References (15)

1. O'Neil J. Securing new drugs for future generations: the pipeline for antibiotics. Available at: http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB-0.pdf. Accessed 21 September 2015.
2. Paduano M. Warning over hospital superbug linked to 16 deaths. Available at: http://www.bbc.co.uk/news/health-26466674. Accessed 21 September 2015.
3. Pfaller MA, Messer SA, Woosley LN, et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010-2011: application of new CLSI clinical breakpoints and epidemiological cut-off values for characterization of geographic and temporal trends in antifungal resistance. J Clin Microb 2013; 51:2571-81.
4. Xiao M, Fan X, Chen SC, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother 2015; 70:802-10.
5. Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida infection: an emerging threat. Interdisc Persp Inf Dis 2014; doi:10.1155/2014/615958.
6. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf# page=49. Accessed 21 September 2015.
7. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf#page=49. Accessed 21 September 2015.
8. Centers for Disease Control and Prevention. Candidiasis. Available at: http://www.cdc.gov/fungal/diseases/candidiasis/index.html. Accessed 21 September 2015.
9. Centers for Disease Control and Prevention. Aspergillosis. Available at: http://www.cdc.gov/fungal/diseases/aspergillosis/index.html. Accessed 21 September 2015.
10. Presidential Council of Advisors on Science and Technology. National Strategy for combatting antibiotic resistant bacteria. Available at: https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast-amr-sept-2014-final.pdf. Accessed 21 September 2015.
11. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13:269-75.
12. Heinz WJ, Cornely O, Franks B, et al. 1133 A phase III, randomized, double-blind trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in hematopoietic stem cell transplant patients with invasive aspergillosis [abstract 1133]. In: American Society of Hematology Annual Meeting, San Francisco, CA, December 2014.
13. Astellas presents new findings for isavuconazole in Mucormycosis at IDWeek. Available at: http://newsroom.astellas.us/2014-10-08-Astellas-Presents-New-Findings-For-Isavuconazole-In-Mucormycosis-At-IDWeek. Accessed 21 September 2015.
14. Basilea reports US FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis. Available at: http://globenewswire.com/news-release/2015/03/06/713280/10123703/en/Basilea-reports-U-S-FDA-approval-of-isavuconazole-for-the-treat ment-of-invasive-aspergillosis-and-invasive-mucormycosis.html. Accessed 21 September 2015.
15. Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE Trials [abstract M-1760]. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014